Clinical trials: Hepatic Tumor Resection
Hepatocellular Carcinoma, Neoplasm Metastasis
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
The purpose of this study is to determine whether capecitabine is effective to prevent disease recurrence after curative hepatic resection in patients with hepatocellular carcinoma.
- Trial name
- NCT00561522
- Testing
- Capecitabine, No other preventive treatment
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Fudan University
Liver Cancer
Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection
The purpose of this study is to help us learn what is the best amount of fluid to administer to patients during liver surgery. Patients will receive either an amount for this surgery based on weight, blood pressure, heart rate…
- Trial name
- NCT01596283
- Testing
- Standard fluid management, Goal directed fluid therapy with the Edwards EV1000 system
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of…
- Trial name
- NCT05407519
- Testing
- Tislelizumab + Sitravatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Provincial Hospital
HCC - Hepatocellular Carcinoma
Recurrence Patterns and Cost-Effectiveness of Surgical Approaches in Early-Stage Hepatocellular Carcinoma
This study aims to investigate the recurrence patterns and cost-effectiveness of robotic-assisted, laparoscopic, and open liver resections in patients with early-stage (BCLC 0/A) hepatocellular carcinoma.
- Trial name
- NCT06776185
- Testing
- Liver Surgery
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Chen Xiaoping
Neoplasms
A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD.
- Trial name
- NCT00264446
- Testing
- ADH300004
- Where
- United States
- Sponsor
- Adherex Technologies, Inc.
Liver Neoplasms, Hepatic Resection
Erector Spinae Plane Block Versus Thoracic Epidural Analgesia for Open Liver Resection
Background: Open liver resection is associated with severe postoperative pain. While thoracic epidural analgesia (TEA) is considered the gold standard for pain control, its clinical application is often limited by postoperative…
- Conditions
- Liver Neoplasms, Hepatic Resection, Liver Cancer
- Trial name
- NCT07642336
- Testing
- Continuous Erector Spinae Plane block, Thoracic Epidural Analgesia (TEA)
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Nguyen Toan Thang
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Neoplasms, Neoplasm Metastasis
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
To evaluate the survival benefit of pre-operation chemotherapy of primary tumor tesection (PTR) compared upfront PTR for colorectal cancer (CRC) patients with an asymptomatic resectable primary tumor and synchronous unresectable…
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms, Chemotherapy; Maternal, Affecting Fetus
- Trial name
- NCT01307878
- Testing
- chemotherapy ± targeted therapy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Fudan University
Liver Cancer (Primary and Metastatic)
A Study of Combination Therapy in Patients With Resectable Liver Cancer
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of an initial combination treatment strategy followed by surgery in patients with cancer.
- Trial name
- Archer (NCT07684040)
- Testing
- Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Hepatocellular Carcinoma
Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. For patients with intermediate HCC (BCLC stage B), transarterial chemoembolization (TACE) has been recommended as the standard therapy in many clinical…
- Trial name
- NCT02616926
- Testing
- Hepatic resection, TACE, RFA
- Where
- 3 sites in China
- Volunteers
- 538 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Esophageal Neoplasms, Cirrhosis
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors.
- Conditions
- Esophageal Neoplasms, Cirrhosis, Portal Hypertension
- Trial name
- NCT04994548
- Testing
- Endosocpic resection of early esophageal tumor
- Volunteers
- 112 people
- Sponsor
- Central Hospital, Nancy, France
Liver Resection
The Evaluation of Surgical Decisions and Prognosis of the Radiomics and Watson Artificial Intelligence in Patients With Hepatocellular Carcinoma
The aim of this study was to evaluate the surgical decisions and prognosis of the radiomics and Watson artificial intelligence in patients with hepatocellular carcinoma.
- Trial name
- NCT03917017
- Testing
- Radiomics and Watson artificial intelligence
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Hepatocarcinoma, Hepatic Metastasis
Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic Surgery
This study aims at assessing the feasibility of Probe-based Confocal Laser Endomicroscopy (pCLE) during laparoscopic hepatic masses resection for intra-operative characterisation of hepatic masses and surgical margins assessment.
- Conditions
- Hepatocarcinoma, Hepatic Metastasis, Hepatic Tumor
- Trial name
- PERSEE (NCT03718078)
- Testing
- Confocal Laser Endomicroscopy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Mauna Kea Technologies
Hepatocellular Carcinoma
Prospective Randomized Trial of Laparoscopic Versus Open Liver Resection for HCC
Short-term outcomes of laparoscopic liver resection is better than those of open liver resection Laparoscopic liver resection is better than open resection in immunological aspects
- Trial name
- HCC (NCT00606385)
- Testing
- Liver resection
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma (HCC)
HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC
This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC).
- Trial name
- HCC-MPDS (NCT07700082)
- Where
- China
- Volunteers
- 555 people
- Sponsor
- Anhui Provincial Hospital
Cholangiocarcinoma Non-resectable
Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocarcinoma
This is a prospective, multicenter, single-arm study investigating the efficacy and safety of preoperative right hepatic artery embolization (PHAE) followed by surgical resection in patients with locally advanced Bismuth IIIb or…
- Trial name
- PHAE-PHCC (NCT07326189)
- Testing
- Preoperative Right Hepatic Artery Embolization
- Volunteers
- 33 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Liver Neoplasms, Postoperative Complications
Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study
Liver resection is an important surgical treatment for patients with liver diseases. Despite advances in surgical and anesthetic management, postoperative complications remain a major concern and may affect patient recovery.
- Trial name
- NCT07719933
- Testing
- terlipressin
- Where
- China
- Volunteers
- 161 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection
Hepatic resection is the most effective curative treatment for resectable HCC, whereas frequent recurrence usually impaired the efficacy of hepatic resection and contributed poor survivals.
- Trial name
- NCT03914352
- Testing
- PD-1 antibody, TACE
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cancer Hospital of Guangxi Medical University
Hepatocarcinoma
Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas
The aim of this study is to assess the benefit of 3D models in the planning of hepatic resection by comparing the changes in the surgical plan based on the analysis of conventional preoperative images (CT-scan and MRI), compared…
- Trial name
- 3D-HAPPI (NCT03382327)
- Testing
- Surgical planning
- Where
- 12 sites in France
- Volunteers
- 136 people
- Sponsor
- IHU Strasbourg
Carcinoma, Hepatocellular
Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection
In this phase 2 study, we aim to evaluate the effects and safety of adjuvant apatinib therapy for the patients who underwent R0 resection for hepatocellular carcinoma with portal vein tumor thrombus.
- Trial name
- NCT03261791
- Testing
- Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital